Bottom line
FHLC vs QAAGZX: the short answer
FHLC (Fidelity MSCI Health Care Index ETF) and QAAGZX (T. Rowe Price Health Sciences Portfolio) share a meaningful slice of their top holdings — about 79% by weight.
FHLC is cheaper at 0.084% vs 0.86% — a difference of $78 a year per $10,000 invested.
Over five years, FHLC returned +7.2% a year vs +4.1% for QAAGZX (reporting dates differ).
Updated Nov 19, 2026
FHLC vs QAAGZX side by side
| FHLC | QAAGZX | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Fidelity | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.084% | 0.86% |
| Annual cost per $10k | $8.4 | $86 |
| 10-yr cost on $10k (prospectus) | $108 | $1,061 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +2.6% | +18.1% |
| 5-yr return (annualized) | +7.2% | +4.1% |
| 10-yr return (annualized) | +8.8% | +9.0% |
| Best quarter | +16.4% | +23.4% |
| Worst quarter | −13.1% | −15.8% |
| Net assets (fund) | $3.3B | $751.7M |
| Number of holdings | 337 | 277 |
| Portfolio turnover | 3% | 65% |
| Returns as of | Nov 30, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FHLC | QAAGZX | Difference |
|---|---|---|---|
| 2024 | +2.6% | +1.7% | +0.9% |
| 2023 | +2.5% | +3.0% | −0.5% |
| 2022 | −5.5% | −12.5% | +7.0% |
| 2021 | +20.4% | +13.1% | +7.3% |
| 2020 | +18.1% | +29.6% | −11.5% |
| 2019 | +21.9% | +29.0% | −7.0% |
| 2018 | +5.5% | +1.1% | +4.4% |
| 2017 | +23.3% | +27.6% | −4.3% |
| 2016 | −3.3% | −10.5% | +7.2% |
Source: Fund prospectus bar charts
Holdings overlap
17 of FHLC's top 25 holdings also appear in QAAGZX's top 25.
| Holding | FHLC | QAAGZX |
|---|---|---|
| Eli Lilly & Co | 13.35% | 14.06% |
| Johnson & Johnson | 8.93% | 6.64% |
| AbbVie Inc | 6.42% | 5.12% |
| UnitedHealth Group Inc | 5.44% | 5.88% |
| Merck & Co Inc | 4.66% | 4.00% |
| Thermo Fisher Scientific Inc | 3.09% | 2.53% |
| Amgen Inc | 3.00% | 1.80% |
| Abbott Laboratories | 2.66% | 1.91% |
| Gilead Sciences Inc | 2.34% | 2.79% |
| Bristol-Myers Squibb Co | 1.93% | 2.12% |
| CVS Health Corp | 1.92% | 0.93% |
| Intuitive Surgical Inc | 1.82% | 1.89% |
| Danaher Corp | 1.80% | 1.44% |
| Vertex Pharmaceuticals Inc | 1.76% | 2.26% |
| Stryker Corp | 1.62% | 1.78% |
Source: SEC Form N-PORT
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
QAAGZX top 10
- Eli Lilly & Co — 14.06%
- Johnson & Johnson — 6.64%
- Unitedhealth Group Inc — 5.88%
- Abbvie Inc — 5.12%
- Merck & Co. Inc. — 4.00%
- Gilead Sciences Inc — 2.79%
- Thermo Fisher Scientific Inc — 2.53%
- Vertex Pharmaceuticals Inc — 2.26%
- Bristol-myers Squibb Co — 2.12%
- Abbott Laboratories — 1.91%
FAQ
What is the difference between FHLC and QAAGZX?
Which is cheaper, FHLC or QAAGZX?
Should I own both FHLC and QAAGZX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.